Ghandili, S.; Schönlein, M.; Lütgehetmann, M.; Schulze zur Wiesch, J.; Becher, H.; Bokemeyer, C.; Sinn, M.; Weisel, K.C.; Leypoldt, L.B.
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. Cancers 2021, 13, 3800.
https://doi.org/10.3390/cancers13153800
AMA Style
Ghandili S, Schönlein M, Lütgehetmann M, Schulze zur Wiesch J, Becher H, Bokemeyer C, Sinn M, Weisel KC, Leypoldt LB.
Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. Cancers. 2021; 13(15):3800.
https://doi.org/10.3390/cancers13153800
Chicago/Turabian Style
Ghandili, Susanne, Martin Schönlein, Marc Lütgehetmann, Julian Schulze zur Wiesch, Heiko Becher, Carsten Bokemeyer, Marianne Sinn, Katja C. Weisel, and Lisa B. Leypoldt.
2021. "Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment" Cancers 13, no. 15: 3800.
https://doi.org/10.3390/cancers13153800
APA Style
Ghandili, S., Schönlein, M., Lütgehetmann, M., Schulze zur Wiesch, J., Becher, H., Bokemeyer, C., Sinn, M., Weisel, K. C., & Leypoldt, L. B.
(2021). Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment. Cancers, 13(15), 3800.
https://doi.org/10.3390/cancers13153800
